Cell Cryopreservation Market Global Industry Insights
The research report on cell cryopreservation market categorizes the global market by product type (Cryopreservative Medium (Glycerol, Dimethyl sulfoxide (DMSO), and Others), Freezers, and Others), by application (Stem cells, Oocytes and embryos, Sperm, Semen, and Testicular Tissue, and Others), by end user (Pharmaceutical and Biotechnology Companies, Research Institutes, and Others) and by Region.
Cryopreservation is a technique used to preserve various cells, tissue, organelles, and other biological products by cooling them at very low temperatures. Cryopreservation uses very low temperatures to preserve structurally intact living cells and tissues for a prolonged time period. Stem cells and various valuable tissues used in research studies and many other medical application are preserved by cryopreservation, as they cannot be stored by simple cooling for a long time. The cryopreservation procedure involves mixing of cryoprotective agents (CPAs) with cells or tissues before cooling, then the cells or tissues are cooled at very low temperature and stored. Cryopreservation has a wide application in preservation of stem cells, oocytes, embryos sperm, semen, testicular tissue, and hepatocytes.
Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/1698
Cell Cryopreservation Market Drivers
Launches of novel cryopreservation systems are expected to be major driver for growth of global cell cryopreservation market. For instance, in 2015, AMS Biotechnology Limited launched its new Stem-Cellbanker, a GMP grade cell cryopreservation media. Stem-Cellbanker is a freezing solution, used for preservation of stem cell, iPS cell and other cells. In 2014, Asymptote Ltd, a Cambridge-based cryopreservation specialists launched its unique range of liquid nitrogen free controlled rate freezers especially designed for the needs of regenerative medicine at the annual meeting of the International Society for Cellular Therapy (ISCT) held in Paris. In 2013, Taiyo Nippon Sanso Corporation launched its latest CryoLibrary (CAPS-i3000), a fully-automated cryopreservation system for cryopreservation of Induced Pluripotent Stem Cell (iPS). Moreover, this field has gained significant traction from funding agencies such as venture capitals and startups, which have successfully raised funding for development of novel cell cryopreservation systems. For instance, in January 2018, VitriCell SA, a biotech company providing innovative cryopreservation solutions closed a series A round funding of US$ 1.2 million from various investors. VitriCell SA will use this fund to launch the first products based on aseptic vitrification, a new cell cryopreservation method. Furthermore, the approval of cryopreserved cells by regulatory bodies is also expected to increase demand for cell cryopreservation system. For instance, in 2017, U.S. Food and Drug Administration (FDA) approved ReNeuron Group Plc. cryopreserved formulation of Human Retinal Progenitor Cell (hRPC).
Cell Cryopreservation Market Regional Analysis
North America is expected to hold a dominant position in global cell cryopreservation market, owing to presence of key players in the region and frequent launches of latest cryopreservation media. For instance, in 2014, irvine scientific a U.S.-based innovator and manufacturer of cell culture media expanded its cell cryopreservation media product portfolio with the launch of PRIME-XV FreezIS DMSO-Free, a Dimethyl Sulfoxide (DMSO) and animal-derived components free cryopreservation solution for Human Mesenchymal Stem/Stromal Cells (MSCs). Furthermore, the Europe is expected to witness a significant growth in global cell cryopreservation market over the forecast period, owing to strategic collaborations and acquisition by the key players in the region. For instance, in 2017, U.K.-based GE healthcare acquired Asymptote Ltd., with this strategic acquisition GE healthcare has expanded its product portfolio with the Asymptote Ltd’s cell cryopreservation system.
Cell Cryopreservation Market Restraint
Launch of alternative cell cryopreservation methods is expected to be the major factor hindering growth of global cell cryopreservation market in near future. For instance, in 2017, Osiris Therapeutics, Inc. launched new Prestige Lyotechnology, a novel method for preservation of living cells and tissues. Launches of such alternative of cell cryopreservation can hinder the growth of market.
Ask for detailed Sample of the Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1698
Cell Cryopreservation Market Key Players
Key players operating in cell cryopreservation market include Merck KGaA, GE Healthcare, Thermo Fisher Scientific, Inc., AMS Biotechnology Limited, Nippon Genetics, VitriCell SA, Miltenyi Biotec, Mediatech, Inc., BioLifeSolutions, Inc., HiMedia Laboratories, and PromoCell GmbH. Key players operating in the market are involved in strategic mergers and collaboration to expand their product portfolio and increase its product presence in key geography. For instance, in 2013, Nippon Zenyaku Kogyo Co., Ltd and Takara Bio Inc. entered into a distribution agreement. As per the agreement Takara Bio Inc. will market Zenoaq's Cellbanker series of cell cryopreservation media exclusively in Japan and non-exclusively in Europe and North America.
Visit our news Website: http://www.coherenttimes.org
Source: Free Articles from ArticlesFactory.com
ABOUT THE AUTHOR
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.